|
1
|
Are C, Rajaram S, Are M, et al: A review
of global cancer burden: trends, challenges, strategies and a role
for surgeons. J Surg Oncol. 107:221–6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cunningham D, Allum WH, Stenning SP, et
al: MAGIC Trial Participants: Perioperative chemotherapy versus
surgery alone for resectable gastroesophageal cancer. N Engl J Med.
355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ychou M, Boige V, Pignon JP, et al:
Perioperative chemotherapy compared with surgery alone for
resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD
multicenter phase III trial. J Clin Oncol. 29:1715–21. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ruan K, Fang X and Ouyang G: MicroRNAs:
novel regulators in the hallmarks of human cancer. Cancer Lett.
285:116–126. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang F, Sun GP, Zou YF, Hao JQ, Zhong F
and Ren WJ: MicroRNAs as promising biomarkers for gastric cancer.
Cancer Biomark. 11:259–267. 2012.PubMed/NCBI
|
|
7
|
Ueda T, Volinia S, Okumura H, et al:
Relation between microRNA expression and progression and prognosis
of gastric cancer: a microRNA expression analysis. Lancet Oncol.
11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li X, Zhang Y, Zhang Y, Ding J, Wu K and
Fan D: Survival prediction of gastric cancer by a seven-microRNA
signature. Gut. 59:579–585. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu K, Qian T, Tang L, Wang J, Yang H and
Ren J: Decreased expression of microRNA let-7i and its association
with chemotherapeutic response in human gastric cancer. World J
Surg Oncol. 10:2252012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu R, Zhang C, Hu Z, et al: A
five-microRNA signature identified from genome-wide serum microRNA
expression profiling serves as a fingerprint for gastric cancer
diagnosis. Eur J Cancer. 47:784–791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu H, Zhu L, Liu B, et al: Genome-wide
microRNA profiles identify miR-378 as a serum biomarker for early
detection of gastric cancer. Cancer Lett. 316:196–203. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Song MY, Pan KF, Su HJ, et al:
Identification of serum microRNAs as novel non-invasive biomarkers
for early detection of gastric cancer. PLoS One. 7:e336082012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song J, Bai Z, Zhang J, et al: Serum
microRNA-21 levels are related to tumor size in gastric cancer
patients but cannot predict prognosis. Oncol Lett. 6:1733–1737.
2013.PubMed/NCBI
|
|
14
|
Xu X, Yang X, Xing C, Zhang S and Cao J:
miRNA: The nemesis of gastric cancer (Review). Oncol Lett.
6:631–641. 2013.PubMed/NCBI
|
|
15
|
Tong F, Cao P, Yin Y, Xia S, Lai R and Liu
S: MicroRNAs in gastric cancer: from benchtop to bedside. Dig Dis
Sci. 59:24–30. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu HH, Lin WC and Tsai KW: Advances in
molecular biomarkers for gastric cancer: miRNAs as emerging novel
cancer markers. Expert Rev Mol Med. 16:e12014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours (7th). Wiley-Blackwell.
Oxford: 2009.
|
|
18
|
Becker K, Reim D, Novotny A, et al:
Proposal for a multifactorial prognostic score that accurately
classifies 3 groups of gastric carcinoma patients with different
outcomes after neoadjuvant chemotherapy and surgery. Ann Surg.
256:1002–1007. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miller R and Siegmund D: Maximally
selected chi-square statistics. Biometrics. 38:1011–1016. 1982.
View Article : Google Scholar
|
|
20
|
Halpern J: Maximally selected chi-square
statistics for small samples. Biometrics. 38:1017–1023. 1982.
View Article : Google Scholar
|
|
21
|
Yasui W, Oue N, Aung PP, Matsumura S,
Shutoh M and Nakayama H: Molecular-pathological prognostic factors
of gastric cancer: a review. Gastric Cancer. 8:86–94. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pietrantonio F, De Braud F, Da Prat V, et
al: A review on biomarkers for prediction of treatment outcome in
gastric cancer. Anticancer Res. 33:1257–1266. 2013.PubMed/NCBI
|
|
23
|
Shen Y, Tang D, Yao R, et al: microRNA
expression profiles associated with survival, disease progression
and response to gefitinib in completely resected non-small-cell
lung cancer with EGFR mutation. Med Oncol. 30:7502013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Preis M, Gardner TB, Gordon SR, et al:
MicroRNA-10b expression correlates with response to neoadjuvant
therapy and survival in pancreatic ductal adenocarcinoma. Clin
Cancer Res. 17:5812–5821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao R, Wu J, Jia W, et al: Plasma miR-221
as a predictive biomarker for chemoresistance in breast cancer
patients who previously received neoadjuvant chemotherapy.
Onkologie. 34:675–680. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Garofalo M, Quintavalle C, Romano G, Croce
CM and Condorelli G: miR221/222 in cancer: their role in tumor
progression and response to therapy. Curr Mol Med. 12:27–33. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nagano H, Tomimaru Y, Eguchi H, et al:
MicroRNA-29a induces resistance to gemcitabine through the
Wnt/β-catenin signaling pathway in pancreatic cancer cells. Int J
Oncol. 43:1066–1072. 2013.PubMed/NCBI
|
|
28
|
Odenthal M, Bollschweiler E, Grimminger
PP, et al: MicroRNA profiling in locally advanced esophageal cancer
indicates a high potential of miR-192 in prediction of
multimodality therapy response. Int J Cancer. 133:2454–2463. 2013.
View Article : Google Scholar : PubMed/NCBI
|
